Patent · US Active

Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

US8415362B2 · kind B2 · utility

100Cited by

34References

21Claims

0Family size

Assignee

Incyte Corporation · US

Inventors

James D. Rodgers · Landenberg, US
Stacey Shepard · Wilmington, US
Thomas P. Maduskuie, Jr. · Wilmington, US
Haisheng Wang · Hockessin, US
Nikoo Falahatpisheh · Wilmington, US
Maria Rafalski · Wilmington, US
Argyrios G. Arvanitis · Kennett Square, US
Louis Storace · Middletown, US
Ravi Kumar Jalluri · San Diego, US

Key dates

Filing date	Jun 12, 2008
Grant date	Apr 9, 2013
Priority date	—
Expiry date	Jun 7, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/05
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines of Formula I:that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.